Remote Ischaemic Preconditioning: A Clinical Evidence Update
A decade after promising mechanistic and pilot data, where does remote ischaemic preconditioning actually stand in cardiac and non-cardiac surgery?
- Published
- 2 May 2026
- Read time
- 3 min read
Remote ischaemic preconditioning (RIPC) — brief, non-injurious episodes of limb ischaemia delivered before a planned ischaemic insult to a distant organ — is one of the most studied "free" cardioprotective interventions of the last two decades. The clinical story has been a humbling one.
The mechanism
Repeated 5-minute cycles of upper-limb ischaemia (typically a BP cuff inflated to 200 mmHg, three to four cycles) trigger a systemic protective phenotype involving humoral mediators (adenosine, bradykinin, opioids), neural pathways (vagal), and intracellular signalling (RISK and SAFE kinase cascades). In animal models the effect is robust: ~30-50% reduction in infarct size after coronary occlusion.
The cardiac surgery trials
Two large 2015 trials largely closed the door on routine RIPC in cardiac surgery:
- ERICCA (n=1612) — CABG with cardiopulmonary bypass. No difference in the composite of CV death, MI, stroke, or revascularisation at 12 months.
- RIPHeart (n=1403) — broader cardiac surgery. No difference in a composite of death, MI, stroke, or AKI.
Evidence
Multiple subsequent meta-analyses have failed to demonstrate a clinically meaningful reduction in hard outcomes in cardiac surgery with RIPC. The effect, if any, is small and probably eclipsed by background anaesthetic and surgical practice (e.g. propofol's confounding cardioprotective effect).
Where signals remain
- STEMI / primary PCI: smaller trials and a 2017 meta-analysis suggested infarct-size reduction by MRI but no consistent clinical-outcome benefit. The CONDI-2/ERIC-PPCI trial (2019, n=5401) was negative for cardiac death or HF hospitalisation at 12 months.
- Vascular surgery: mixed signals, no large definitive trial.
- Renal protection in contrast media exposure: heterogeneous trials, no clear consensus.
Why might it have failed clinically?
The animal-to-human translation gap is the standard answer but probably incomplete. Plausible specifics:
- Co-medication confounding — propofol, opioids, and volatiles share signalling pathways with RIPC.
- Patient heterogeneity — diabetes, age, statins, hypertension all attenuate the conditioning response.
- Underpowered for "hard" outcomes — most positive signals were on surrogate endpoints (troponin AUC, MRI infarct size).
- Implementation drift — the protocol (number of cycles, timing relative to insult) varied between trials.
What to do now
RIPC is not routinely recommended in current guidelines for cardiac surgery, PCI, or peri-operative care. It remains:
- Safe — adverse events are negligible.
- Cheap — a BP cuff and a clock.
- Mechanistically interesting — particularly when paired with novel cardioprotective agents.
Clinical pearl
If a colleague is enthusiastic about RIPC for a high-risk cardiac surgical patient, the honest answer is: it's safe, it's free, the evidence does not support a benefit on hard outcomes, but it is not harmful either. Make the decision on case-by-case basis, not policy.
Where the field is going
Pharmacological mimics of conditioning (e.g. exenatide, ciclosporin, MTP-131) and combination therapies (RIPC + targeted temperature management, RIPC + post-conditioning) are the most active research directions. None have crossed the threshold into routine practice. A clinically useful, replicable cardioprotective adjunct beyond reperfusion itself remains an open problem.
Key points
- RIPC is mechanistically robust in animals but clinically negative in the largest human trials (ERICCA, RIPHeart, CONDI-2/ERIC-PPCI).
- It is safe and cheap, but not part of current guidelines.
- Confounding by anaesthesia and patient comorbidity probably contributes to translation failure.
- The cardioprotective adjunct space remains an open research question.
References
- [1]Hausenloy DJ, Candilio L, Evans R, et al. Remote ischemic preconditioning and outcomes of cardiac surgery (ERICCA). N Engl J Med. 2015;373(15):1408-1417. Link
- [2]Meybohm P, Bein B, Brosteanu O, et al. A multicenter trial of remote ischemic preconditioning for heart surgery (RIPHeart). N Engl J Med. 2015;373(15):1397-1407. Link
- [3]Hausenloy DJ, Yellon DM. Ischaemic conditioning and reperfusion injury. Nat Rev Cardiol. 2016;13(4):193-209. Link
About the author
Dr. Imani OkoroVerifiedVerified medical practitioner
MBBS, MRCP, PhD
Consultant cardiologist with a research interest in heart failure pharmacotherapy and remote monitoring. Edits the cardiology stream for MedSchool.
More in Cardiology
Managing Acute Decompensated Heart Failure on the Ward
A practical ward-level framework for the patient with acute decompensated heart failure — assessment, diuresis, and the early decisions that matter most.
Omega-3s in Cardiovascular Prevention: What the Evidence Says
A pragmatic synthesis of where omega-3 fatty acid supplementation sits in cardiovascular prevention after REDUCE-IT, STRENGTH, and the secondary-prevention meta-analyses.
Heart Failure Pharmacotherapy: The Four Pillars in Practice
A practical summary of guideline-directed medical therapy for HFrEF — the four pillars, how to initiate, and what order to titrate when the patient is in clinic.